Biopharma AI
By
FDA Qualifies First AI Drug Development Tool, Will Be Used in ‘MASH’ Clinical Trials to Accelerate Liver Disease Drug Development
The U.S. Food and Drug Administration (FDA) has qualified AIM-NASH, the first AI-based tool designed to assist doctors…
How Novartis and Relation Therapeutics’ $1.7 Billion AI Collaboration Redefine Drug Discovery Success Rates in Immunology, Atopic Diseases?
Key Highlights: • AI-driven, patient-derived target discovery emerges as a new gold standard for reducing late-stage clinical failures•…
How Roche’s $55 Million Bet on Manifold Bio’s AI Brain-Shuttle Platform Unlock the Next Trillion-Dollar Neuroscience Opportunity?
Key Highlights• Roche deepens its AI-first drug discovery strategy with a foundational partnership targeting blood-brain barrier (BBB) breakthroughs•…
Will Lilly’s AI Supercomputer with NVIDIA Become the Breakthrough That Redefines Competitive Timelines in Drug Development?
• Lilly partners with NVIDIA to build what it calls the most powerful AI supercomputer operated by a…
Chai Discovery Becomes Newest AI Unicorn Following $130 Million Series B Financing
Company valued at $1.3 billion as investors back AI-native drug discovery platform San Francisco, California Chai Discovery today…
PhaseV Reports Breakthrough Year in 2025, Marking Transition to Scaled AI Deployment in Clinical Development
Boston, Massachusetts PhaseV announced today that 2025 marked a defining year for the company, highlighted by record revenue…
